Author

T. W. Miller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:chromatin & epigenetic regulation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

D. R. Pattabiraman· 2 shared E. Demidenko· 2 shared K. E. Muller· 2 shared M. Bagheri· 2 shared N. A. Traphagen· 2 shared A. E. Goen· 1 shared A. Jiang· 1 shared A. L. Johnson· 1 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. R. Pattabiraman

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylationchanges with potential therapeutic implications for triple-negative breastcancer

M. Bagheri, M. K. Lee, K. E. Muller, T. W. Miller, D. R. Pattabiraman, B. C. Christensen

This study shows eribulin treatment alters DNA methylation and epigenetic modifier expression in TNBC cells, suggesting potential therapeutic use in triple-negative breast cancer.

bioRxiv · Jun 9, 2023 · PreprintCancer Biology

Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression

M. Bagheri, G. A. Mohamed, M. A. Mohamed Saleem, N. B. Ognjenovic, H. Lu, F. W. Kolling, O. M. Wilkins, S. Das, I. S. LaCroix, S. H. Nagaraj, K. E. Muller, S. A. Gerber, T. W. Miller, D. R. Pattabiraman

The paper shows that eribulin induces MET in mesenchymal-like TNBC cells, reducing metastatic potential and increasing sensitivity to other chemotherapeutics.

bioRxiv · Apr 19, 2023 · PreprintCancer Biology

Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer

N. A. Traphagen, G. N. Schwartz, S. Tau, A. Jiang, S. R. Hosford, A. E. Goen, A. M. Roberts, B. A. Romo, A. L. Johnson, E.-C. K. Duffy, E. Demidenko, P. Heverly, Y. Mosesson, S. M. Soucy, F. Kolling, T. W. Miller

This study shows estrogen therapy induces DNA damage in ER+ breast cancer cells, which can be enhanced by PARP inhibition to improve treatment outcomes.

bioRxiv · Mar 16, 2023Cancer Biology

AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells

R. A. Hampsch, J. D. Wells, N. A. Traphagen, C. F. McCleery, J. L. Fields, K. Shee, L. M. Dillon, D. B. Pooler, L. D. Lewis, E. Demidenko, Y. H. Huang, J. D. Marotti, W. Kinlaw, T. W. Miller

This study shows that metformin promotes survival of dormant ER+ breast cancer cells by increasing mitochondrial respiration through fatty acid oxidation, suggesting caution in using AMPK activators with anti-estrogens.

bioRxiv · Jan 21, 2020Cancer Biology

A Homogeneous SIRPα-CD47 Cell-Based, Ligand-Binding Assay: Utility for Small Molecule Drug Development in Immuno-oncology.

T. Burgess, J. Amason, J. Rubin, D. Duveau, L. Lamy, D. Roberts, C. Farrell, J. Inglese, C. Thomas, T. W. Miller

This paper develops a cell-based ligand-binding assay to identify small molecule inhibitors of the SIRP-CD47 interaction for immuno-oncology drug development.

bioRxiv · Dec 5, 2019Immunology